Is BPC-157 Legal in Georgia?

Print or save as PDF

See the public record for BPC-157

The federal position

No FDA-approved medicine contains BPC-157, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [8].

On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, BPC-157 sits in none of the three categories. Category 1 is the group FDA says it generally will not act against compounders for, if conditions are met, so that policy does not cover BPC-157 [2]. Large registered outsourcing facilities use a separate FDA list, and BPC-157 is not on it [3].

BPC-157 was on FDA's category 2 list of bulk substances that may present significant safety risks from September 2023 until April 22, 2026. It then moved to a nominated-but-withdrawn table because the nominators withdrew; removal was not a finding of safety [9]. FDA's stated concerns stay on that page, including that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and that FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [9].

The 2026 advisory vote and draft policy

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation [6][5]. Staff had cited poor chemical characterization, limited safety and immunogenicity information, and insufficient evidence for the ulcerative colitis use FDA evaluated [1]. The vote is advice only; BPC-157 is not on the list, and adding it needs formal rulemaking [5].

HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy covering six peptides, BPC-157 among them [4][5]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with one while FDA's list is developed through rulemaking, if the conditions are met [4]. For BPC-157 those conditions include:

• BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms
• a single active ingredient
• bulk substance from an FDA-registered manufacturer with a valid certificate of analysis
• the label wording 'This is a compounded drug product. Not for resale.'
• a patient-specific prescription
• MedWatch reporting of serious adverse events and quality problems
• documentation of adequate bioavailability for oral forms [5]

The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' [4]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [4][5].

Safety

FDA found five small human studies and concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, with no human studies of oral, subcutaneous, nasal or skin use [1]. A 2026 systematic review found three human studies, 30 patients total, all of poor methodological quality with very low certainty [10].